Solid Biosciences Inc.
SLDBHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeSolid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. With a market capitalization of $858.5M, it sits in small-cap territory. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy.
Market Cap
$858.5M
Beta
2.36
P/E (TTM)
—
P/E (Fwd)
-4.45
EPS (TTM)
$-1.85
EPS (Fwd)
$-1.96
ROE
-57.4%
ROA
-32.0%
Cash
$380.7M
Total Debt
$20.7M
Free CF
-$111.0M
52W Change
36.5%
Annual Financials
Cash vs Debt
With $380.7M in cash and $20.7M in debt, SLDB maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$111.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -57.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $8.1M (2022) to $0 (2025), a 100% decline worth watching.
Solid Biosciences Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, SLDB has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Solid Biosciences Inc. and its sector.